IN PARTNERSHIP
SMART digital adherence technology (DAT): improving the speed and accuracy of clinical trials
Medication adherence is a global challenge for healthcare providers that impacts budgets and patient treatment. WestRock reveals why SMART packaging solutions could improve outcomes.
T
he importance of patient adherence to medication is recognised as a key to improved health outcomes across drug
development and in clinical practice. The World Health Organization (WHO) concludes that increasing the effectiveness of adherence interventions may have a far greater impact on the health of the population than any 1
.
Current methods of improving medication adherence are typically complex, labour- of drug development far too many clinical trials fail or become delayed, and these failures and delays are not always due to poor drug adherence to medication. The challenge of non-adherence, further exacerbated by increased implementation of
“Digital health and outpatient sampling technologies have the potential to shift the paradigm toward more patient-centric clinical trials. We expect the industry is headed toward a future where use of such tools is expected and required in drug development trials versus ‘nice to have’ inclusions”9
82 | Outsourcing in Clinical Trials Handbook
decentralised clinical trials and global trends towards patient empowerment, offers tremendous potential for electronically enabled SMART packaging solutions. These SMART solutions deliver evidence- based adherence data critical to driving the speed and accuracy of clinical trials, while empowering clinicians and patients. adherence solutions based on SMART packages can help improve patient medication adherence in both clinical trials and in clinical practice. In clinical trials, electronically enabled packaging solutions can help optimise patient adherence to the study product through informed package design and can generate reliable and granular adherence data, thus improving statistical power and reducing the risk of post-approval dose reductions. Ultimately, protocol designs that implement
and can yield more accurate results, improving the pathway to commercialisation. In the pharmaceutical trade, these innovations can foster enhanced patient engagement and elevate a brand’s digital health initiatives.
Patient medication adherence: a major challenge Poor medication adherence has a dramatic negative impact on clinical trial results. Non-adherence can lead to substantially adverse consequences – on both study data as well as trial outcomes. The WHO estimates that, in developed countries, only half of patients who
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100
